RaQualia Pharma Inc. - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 43 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

RaQualia Pharma Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'RaQualia Pharma Inc. - Product Pipeline Review - 2014', provides an overview of the RaQualia Pharma Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of RaQualia Pharma Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of RaQualia Pharma Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of RaQualia Pharma Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the RaQualia Pharma Inc.'s pipeline products

Reasons to buy

- Evaluate RaQualia Pharma Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of RaQualia Pharma Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the RaQualia Pharma Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of RaQualia Pharma Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of RaQualia Pharma Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of RaQualia Pharma Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
RaQualia Pharma Inc. Snapshot 5
RaQualia Pharma Inc. Overview 5
Key Information 5
Key Facts 5
RaQualia Pharma Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
RaQualia Pharma Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
RaQualia Pharma Inc. - Pipeline Products Glance 13
RaQualia Pharma Inc. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
RaQualia Pharma Inc. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
RaQualia Pharma Inc. - Drug Profiles 17
RQ-00000004 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
RQ-00000010 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
RQ-00000774 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
RQ-00201894 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
RQ-00202730 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
RQ-00203066 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
RQ-00310941 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
RQ-00432933 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Drugs to Modulate Specific Ion Channel for Pain 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Nav 1.7 Blocker Program 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Nav1.8 Sodium Channel Blocker For Pain 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecule to Modulate Specific Ion Channel for an Undisclosed Indication 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecules to Antagonize TRPM8 for Neuropathic Pain 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
T-Ca (Cav3.2) Blocker Program 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
RaQualia Pharma Inc. - Pipeline Analysis 31
RaQualia Pharma Inc. - Pipeline Products by Target 31
RaQualia Pharma Inc. - Pipeline Products by Route of Administration 33
RaQualia Pharma Inc. - Pipeline Products by Molecule Type 34
RaQualia Pharma Inc. - Pipeline Products by Mechanism of Action 35
RaQualia Pharma Inc. - Recent Pipeline Updates 37
RaQualia Pharma Inc. - Dormant Projects 40
RaQualia Pharma Inc. - Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43

List of Tables
RaQualia Pharma Inc., Key Information 5
RaQualia Pharma Inc., Key Facts 5
RaQualia Pharma Inc. - Pipeline by Indication, 2014 7
RaQualia Pharma Inc. - Pipeline by Stage of Development, 2014 9
RaQualia Pharma Inc. - Monotherapy Products in Pipeline, 2014 10
RaQualia Pharma Inc. - Out-Licensed Products in Pipeline, 2014 11
RaQualia Pharma Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 12
RaQualia Pharma Inc. - Phase II, 2014 13
RaQualia Pharma Inc. - Phase I, 2014 14
RaQualia Pharma Inc. - Preclinical, 2014 15
RaQualia Pharma Inc. - Discovery, 2014 16
RaQualia Pharma Inc. - Pipeline by Target, 2014 32
RaQualia Pharma Inc. - Pipeline by Route of Administration, 2014 33
RaQualia Pharma Inc. - Pipeline by Molecule Type, 2014 34
RaQualia Pharma Inc. - Pipeline Products by Mechanism of Action, 2014 36
RaQualia Pharma Inc. - Recent Pipeline Updates, 2014 37
RaQualia Pharma Inc. - Dormant Developmental Projects,2014 40
RaQualia Pharma Inc., Other Locations 41
RaQualia Pharma Inc., Subsidiaries 41